Suppr超能文献

心脏手术后氯胺酮-右美托咪定和七氟醚-舒芬太尼麻醉对心脏生物标志物影响的比较:一项观察性研究。

Comparison of the effects of ketamine-dexmedetomidine and sevoflurane-sufentanil anesthesia on cardiac biomarkers after cardiac surgery: an observational study.

机构信息

Department of Anesthesiology and Intensive Care Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

出版信息

Physiol Res. 2012;61(1):63-72. doi: 10.33549/physiolres.932224. Epub 2011 Dec 20.

Abstract

Inhalational anesthetics have demonstrated cardioprotective effects against myocardial ischemia-reperfusion injury. Clinical studies in cardiac surgery have supported these findings, although not with the consistency demonstrated in experimental studies. Recent investigations have questioned the advantages of inhalational over intravenous anesthetics with respect to cardiac protection. Ketamine has been shown to be comparable with sufentanil, and has even demonstrated anti-inflammatory properties. Dexmedetomidine has been established as a sedative/anesthetic drug with analgesic properties, and has also demonstrated myocardial protective effects. In this retrospective observational study, the influence of ketamine-dexmedetomidine-based anesthesia (KET-DEX group; n=17) on the release of cardiac biomarkers was compared with that of sevoflurane-sufentanil-based anesthesia (SEVO group; n=21) in patients undergoing elective coronary artery bypass grafting. Compared with the SEVO group, the KET-DEX group exhibited significantly reduced cardiac troponin I (2.22+/-1.73 vs. 3.63+/-2.37 microg/l; P=0.02) and myocardial fraction of creatine kinase (CK-MB) levels (12.4+/-10.4 vs. 20.3+/-11.2 microg/l; P=0.01) on the morning of the first postoperative day. Furthermore, cardiac troponin I release, evaluated as the area under the curve, was significantly reduced in the KET-DEX group (32.1+/-20.1 vs. 50.6+/-23.2; P=0.01). These results demonstrate the cardioprotective effects of ketamine-dexmedetomidine anesthesia compared with those of sevoflurane-sufentanil anesthesia.

摘要

吸入麻醉药已被证明对心肌缺血再灌注损伤具有心脏保护作用。心脏手术的临床研究支持了这些发现,尽管其一致性不如实验研究。最近的研究对吸入麻醉与静脉麻醉在心脏保护方面的优势提出了质疑。氯胺酮已被证明与舒芬太尼相当,甚至具有抗炎作用。右美托咪定已被确立为具有镇痛作用的镇静/麻醉药物,并且还具有心肌保护作用。在这项回顾性观察性研究中,与七氟醚-舒芬太尼基础麻醉(SEVO 组;n=21)相比,比较了基于氯胺酮-右美托咪定的麻醉(KET-DEX 组;n=17)对接受择期冠状动脉旁路移植术的患者中心脏生物标志物释放的影响。与 SEVO 组相比,KET-DEX 组在术后第一天早晨的肌钙蛋白 I(2.22+/-1.73 与 3.63+/-2.37μg/l;P=0.02)和肌酸激酶同工酶(CK-MB)水平(12.4+/-10.4 与 20.3+/-11.2μg/l;P=0.01)显著降低。此外,KET-DEX 组的肌钙蛋白 I 释放(作为曲线下面积评估)也显著降低(32.1+/-20.1 与 50.6+/-23.2;P=0.01)。这些结果表明,与七氟醚-舒芬太尼麻醉相比,氯胺酮-右美托咪定麻醉具有心脏保护作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验